Anika Therapeutics Stock
Anika Therapeutics Stock
There is no change in the price for Anika Therapeutics today.
Anika Therapeutics is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a current price of 12.9 € Anika Therapeutics is right around the predicted target price of 13 €.
Our community identified positive and negative aspects for Anika Therapeutics stock for the coming years. 1 users see the criterium "Brand" as a plus for the Anika Therapeutics stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | 0.000% | -0.769% | 6.612% | 4.878% | 61.250% | -47.131% | -63.559% |
| Heron Therapeutics Inc. | -0.790% | 9.793% | 27.293% | -54.876% | -21.499% | -62.628% | -93.889% |
| Evolus Inc | -0.620% | 13.182% | 16.719% | -56.059% | -17.761% | -42.168% | -41.792% |
| Sangamo Therapeutics Inc. | -29.780% | -28.034% | -47.326% | -77.235% | -53.545% | -89.092% | -98.322% |
Comments
Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $15.00 price target on the stock.
Show more
Ratings data for ANIK provided by MarketBeat